Does Security Health Plan Cover Vyvanse?

How Security Health Plan Handles Vyvanse Coverage

Security Health Plan, based in Marshfield, Wisconsin, operates commercial, Medicare Advantage, and Medicaid managed-care products across the state. Coverage for Vyvanse varies by product line. Most commercial and marketplace plans list Vyvanse on the formulary but classify it as a non-preferred brand, which triggers both higher cost-sharing and utilization management controls like prior authorization.

Commercial vs. Medicare Advantage Differences

On commercial plans, Vyvanse generally sits at Tier 3 (non-preferred brand). Medicare Advantage formularies may exclude Vyvanse or restrict it more tightly because the FDA approval for BED only covers adults, and ADHD stimulant coverage in Medicare populations follows CMS guidance on Part D protected classes. Medicaid managed-care members should check their specific benefit booklet, as Wisconsin Medicaid preferred drug lists differ from commercial formularies.

Why Tier Placement Matters

A Tier 3 placement means Vyvanse costs more out of pocket than a Tier 1 generic stimulant. According to a 2023 analysis in JAMA Network Open, out-of-pocket costs for brand-name ADHD medications averaged $62 per fill nationally, compared to $11 for generics. That gap widens if your plan applies coinsurance (typically 25% to 40%) rather than a flat copay.

Prior Authorization: What Security Health Plan Requires

Nearly all Security Health Plan products require prior authorization (PA) before dispensing Vyvanse. The PA process confirms medical necessity and checks whether you have tried a less expensive alternative first.

Typical PA Criteria

Most plans require documentation of the following:

• A confirmed diagnosis of ADHD (using DSM-5-TR criteria) or moderate-to-severe BED
• Age-appropriate prescribing (6+ for ADHD, 18+ for BED)
• A trial and failure of, or documented contraindication to, at least one generic stimulant (methylphenidate or generic mixed amphetamine salts)
• Prescriber attestation that the patient cannot use an alternative medication

A 2022 study in Pediatrics found that prior authorization requirements for ADHD medications delayed treatment initiation by a median of 14 days. The American Academy of Pediatrics clinical practice guideline recommends that children aged 6 and older with ADHD receive FDA-approved medications as first-line therapy, noting that "evidence-based pharmacotherapy should be initiated promptly once the diagnosis is established."

How to Submit the PA

Your prescriber's office submits the PA electronically or by fax to Security Health Plan's pharmacy benefit manager. You can also call the member services number on the back of your insurance card to check PA status. Decisions typically arrive within 48 to 72 hours for standard requests. Urgent requests can be processed within 24 hours.

Step Therapy Requirements

Step therapy (sometimes called "fail first") is a common barrier. Security Health Plan may require you to try one or two generic alternatives before approving Vyvanse.

Common Step-Therapy Medications

The most frequently required first-step medications include:

• Generic mixed amphetamine salts (Adderall equivalent): Available in immediate-release and extended-release forms. A month's supply costs $15 to $40 with most plans.
• Generic methylphenidate (Ritalin/Concerta equivalent): Also available in multiple formulations. A meta-analysis in The Lancet Psychiatry (N=10,068 across 133 trials) found methylphenidate to be the best-tolerated first-line medication for children with ADHD, while amphetamines (including lisdexamfetamine) showed the largest effect sizes in adults.

When Step Therapy Does Not Apply

Step therapy may be waived if your prescriber documents that generic stimulants caused intolerable side effects, a clinically significant drug interaction exists, or you have a history of substance misuse that makes the abuse-deterrent prodrug design of Vyvanse medically necessary. Lisdexamfetamine's prodrug mechanism requires enzymatic conversion in red blood cells, which limits its abuse potential compared to immediate-release amphetamine formulations. The FDA-approved labeling specifically notes reduced subjective "drug liking" scores versus equivalent doses of d-amphetamine in abuse-liability studies.

Out-of-Pocket Cost Estimates

Without insurance, Vyvanse costs approximately $350 to $450 for a 30-day supply at retail pharmacies. With Security Health Plan coverage, your costs depend on plan design.

Copay vs. Coinsurance Structures

Flat copay plans charge a fixed amount per fill (commonly $50 to $75 for Tier 3). Coinsurance plans charge a percentage, typically 25% to 40%, which on a $400 retail price translates to $100 to $160 before any manufacturer discounts apply.

Reducing Your Costs

Several strategies can lower what you pay:

• Takeda copay savings card: Eligible commercially insured patients can receive up to $60 off per prescription, reducing a $75 copay to $15. Medicare, Medicaid, and other government-insured patients are not eligible.
• Mail-order pharmacy: Security Health Plan offers 90-day mail-order fills. Many plans reduce the per-fill cost for 90-day supplies to 2.5 times the 30-day copay rather than 3 times.
• Preferred pharmacy networks: Using an in-network pharmacy ensures you pay the negotiated rate rather than the full retail price.

A 2021 analysis in the Annals of Internal Medicine reported that patients using manufacturer copay assistance programs saved a median of $53 per brand-name prescription fill but cautioned that these savings do not count toward deductibles in accumulator-adjustment plans.

What Happens If Coverage Is Denied

A denial does not have to be the final word. Security Health Plan members have the right to appeal, and success rates for ADHD medication appeals can be significant when supported by clinical documentation.

Internal Appeal Process

You have 30 calendar days from the denial notice to file a standard internal appeal. Include a letter of medical necessity from your prescriber explaining why Vyvanse is required over alternatives. Attach records of prior medication trials, side-effect documentation, and any relevant clinical notes.

Dr. David Goodman, assistant professor of psychiatry at Johns Hopkins School of Medicine, has stated: "When patients have documented failure on two or more generic stimulants, most plans will approve the brand medication on appeal. The key is thorough documentation from the prescribing clinician."

External Review

If the internal appeal is denied, you can request an independent external review through the Wisconsin Office of the Commissioner of Insurance. External reviewers evaluate whether the plan's decision was consistent with current medical evidence and accepted standards of care.

Expedited Appeals

If your prescriber believes a delay could cause serious harm, an expedited appeal must be decided within 72 hours. This is particularly relevant for patients whose ADHD symptoms are causing functional impairment at work or school while waiting for medication access.

Vyvanse for Binge Eating Disorder Coverage

Vyvanse holds a separate FDA approval for moderate-to-severe BED in adults at doses of 50 mg to 70 mg daily. Security Health Plan coverage for this indication may carry additional requirements.

BED-Specific PA Criteria

Plans typically require:

• A formal BED diagnosis meeting DSM-5-TR criteria (recurrent binge eating episodes at least once weekly for 3 months)
• Documentation that the patient is not using Vyvanse for weight loss (the label carries a specific limitation against use in obesity without BED)
• Evidence that behavioral interventions (cognitive-behavioral therapy) have been tried or are being used concurrently

The key trial data showed lisdexamfetamine 50 mg and 70 mg reduced binge days per week from a baseline of 4.5 to 1.1 and 0.9 respectively, versus 2.3 for placebo (P<0.001, N=724 across two Phase III studies). These findings supported the 2015 FDA approval for this indication.

Coverage Gaps

Some plan designs cover Vyvanse for ADHD but exclude or limit BED coverage. If your plan denies BED coverage, your prescriber can submit a PA specifying the FDA-approved indication and citing the clinical trial evidence. Plans that cover other eating disorder treatments are generally required to apply mental health parity rules under the Mental Health Parity and Addiction Equity Act.

Generic Alternatives and the Patent Field

No generic lisdexamfetamine is currently available in the United States. Takeda's composition-of-matter patent expired in 2023, but subsequent litigation and regulatory proceedings have delayed generic entry.

What Generic Entry Would Mean

When generics do reach the market, Security Health Plan will likely move them to Tier 1 or Tier 2, reducing copays to $10 to $25. The Congressional Budget Office has estimated that generic competition typically reduces drug prices by 80% to 85% once three or more manufacturers enter the market. For patients currently paying $100 or more per fill, generic availability could be a significant shift.

Authorized Generics vs. True Generics

An authorized generic (manufactured by or licensed from Takeda) may appear before independent generics. Authorized generics use the identical formulation but are marketed at a lower price. They are typically placed on a preferred brand tier, which could reduce your copay by $20 to $40 compared to the current brand.

Tips for Working With Security Health Plan

Getting the most out of your coverage requires preparation. Here are concrete steps.

Before Your Appointment

Request a copy of your plan's formulary from the Security Health Plan member portal or by calling member services. Identify where Vyvanse falls on the tier structure and what PA or step-therapy rules apply to your specific plan.

At the Prescriber Visit

Ask your prescriber to document in the medical record why Vyvanse is preferred over generic alternatives. If you have tried generic stimulants before, bring dates, doses, and descriptions of why they did not work. The American Psychiatric Association practice guidelines note that "switching stimulant class or formulation is appropriate when the initial agent produces inadequate response or intolerable adverse effects at optimized doses."

After Submitting the PA

Follow up with your prescriber's office and the plan within 3 to 5 business days. If the PA is approved, confirm the approval duration (typically 6 to 12 months) and set a reminder to renew before expiration. If denied, begin the appeal process immediately to avoid gaps in treatment.

Patients who fill Vyvanse 70 mg once daily at a Security Health Plan preferred pharmacy with a Tier 3 copay of $65 and apply the Takeda savings card pay approximately $5 to $15 per month, making the net cost comparable to many generic stimulants.